" Top 5 Stories of the Week: First Mining Gold (TSX:FF), Algernon Pharmaceuticals (CSE:AGN), G Mining Ventures (TSXV:GMIN), Nextech AR Solutions (CSE:NTAR), Datametrex (TSXV:DM)

While global markets are in a downtrend year to date, return drivers for active investors still abound.
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) achieves co-primary endpoint in its Phase 2 study of Ifenprodil

Algernon Pharmaceuticals (AGN) has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 (Ifenprodil).
Algernon Pharmaceuticals - CEO, Christopher J. Moreau.

" Algernon Pharmaceuticals (CSE:AGN) updates its planned Phase 1 Repirinast Chronic Kidney Disease study

Algernon (AGN) has provided an update on its chronic kidney disease (CKD) research program with NP-251 (Repirinast).
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) updates Phase 1 DMT human stroke study

Algernon (AGN) has provided an update on its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”).

" Algernon Pharmaceuticals Inc. (CSE:AGN) closes public offering of units

Algernon Pharmaceuticals (AGN) has closed its previously announced marketed public offering.

" Algernon Pharmaceuticals (CSE:AGN) announces pricing of public offering

Algernon Pharmaceuticals (AGN) has confirmed the pricing of its previously announced public offering of units.

" Algernon Pharmaceuticals (CSE:AGN) receives patent for Ifenprodil

Algernon Pharmaceuticals (AGN) has been issued a patent for the treatment of interstitial lung disease with NP-120 (Ifenprodil).

" Algernon (CSE:AGN) receives requests for ongoing supply of Ifenprodil from study participants

Patients participating in Algernon Pharmaceuticals’ (AGN) clinical study in Australia and New Zealand have requested Ifenprodil for their personal use.

" Algernon Pharmaceuticals (CSE:AGN) announces public offering of units

Algernon (AGN) has announced a marketed public offering of units with Research Capital as the sole agent and sole bookrunner.

" Algernon Pharmaceuticals (CSE:AGN) locks in Phase 2 results of IPF & chronic cough study

Algernon (AGN) announced that all data from its Phase 2 proof-of-concept study is now reported and has been “locked” in the database.
Algernon Pharmaceuticals - CEO, Christopher J. Moreau.

" Algernon Pharmaceuticals (CSE:AGN) treats last patient in phase 2 IPF and chronic cough study

Algernon (AGN) has treated the last patient in its phase 2 study of IPF and chronic cough.
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) begins manufacturing of Repirinast and launches chronic kidney disease research program

Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251 (Repirinast).

" Algernon Pharmaceuticals (CSE:AGN) completes enrollment in its Phase 2 study of Ifenprodil

Algernon Pharmaceuticals (AGN) has completed enrollment in its Phase 2 NP-120 (Ifenprodil) idiopathic pulmonary fibrosis (IPF) and chronic cough study.
The Market Herald Video

" Introducing Algernon Pharmaceuticals (CSE:AGN)

Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s approach to the psychedelics and health care sectors.

" Algernon Pharmaceuticals (CSE:AGN) receives notice of allowance for Ifenprodil

Algernon Pharmaceuticals Inc. (AGN) receives notice of allowance for Ifenprodil patent application for idiopathic pulmonary fibrosis treatment (IPF).
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) discloses novel salt patent strategy

Algernon Pharmaceuticals (AGN) has included novel salt forms of DMT in its intellectual property patent applications for AP-188 (“N,N-dimethyltryptamine” or “DMT”).
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study

Algernon (AGN) has filed a Clinical Trials of Investigational Medicinal Products and Ethics Approval application with the UK MHRA.
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from the U.S. FDA for its Phase 2b Ifenprodil chronic cough study

Algernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for its investigation of NP-120 (Ifenprodil) for the treatment of chronic cough.

" Algernon (CSE:AGN) receives positive feedback from the U.S. FDA for Ifenprodil

Algernon Pharmaceuticals Inc. (AGN) has received positive feedback from the U.S. FDA for its research on Ifenprodil to treat chronic cough. 

" Algernon Pharmaceuticals (CSE:AGN) completes manufacturing of DMT and appoints UK stroke experts for phase 2 trials

Algernon Pharmaceuticals (AGN) has manufactured a supply of clinical-grade AP-188 DMT for its planned phase 1 and phase 2 clinical trials.